I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine
|
|
- Neil Maxwell
- 5 years ago
- Views:
Transcription
1 Molecular Characterization of Stage 1-3 Melanoma: Are we close to accurate prognostication and prediction? I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine
2 COI Disclosure: I have received support from the following companies: Merck Samumed Novartis Rohto Pharmaceuticals Galderma Piqur Co-owner of patent with UPenn to use SMKIs topically to treat skin cancers Myriad Genetics, speaker
3 Objectives: Briefly discuss some recent changes to AJCC staging system for early stage melanoma Discuss genetic and molecular tests for stage 1-3 melanomas
4 Changes for 2018 Mitoses are no longer used to stratify tumor staging Instead, for lesions <1mm, thickness of 0.8mm is used for stratification Stage IA: no ulceration, <0.8mm Stage IB: ulceration OR 0.8 1mm <0.8mm, -ulceration = IA <0.8mm, +ulceration = IB 0.8-1mm (regardless of ulceration) = IB
5 Mitoses remain significant Among patients with clinically node-negative (cn0) primary melanoma in the 8th edition database, increasing mitotic rate was significantly associated with decreasing MSS in univariate analysis Gershenwald et al, Ca Cancer J Clin 2017
6 Early prognostic models: Model predicting survival in stage I melanoma based on tumor progression. Clark WH Jr 1, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. J Nat Cancer Inst patients with VGP stage 1 melanomas with over 100 month follow up Found that 6 variables: mitotic rate/mm 2, thickness, TILs, anatomic site, patient sex and regression predicted 8-year survival with 89% accuracy.
7 Molecular analysis of melanoma for diagnosis and prognosis: 1) B-Raf mutational analysis 2) Comparative genomic hybridization (CGH) 3) Fluorescence in situ hybridization (FISH) 4) Gene expression profiling to determine if melanocytic lesion is melanoma 5) Gene expression profiling to determine metastatic risk
8 Why is BRAF testing performed? 50-60% of melanomas harbor mutations at codon 600 Valine (V) to glutamic acid (E) substitution most common mutation at position 600 = V600E (90%) 2 nd most common mutation is V600K (valine lysine) Mutation results in constitutive activation of the MAP kinase signaling pathway = dysregulated tumor growth V600E/K mutations confer increased sensitivity to BRAF inhibitors (vemurafenib, dabrafenib)
9 How is BRAF testing performed? PCR-based BRAF V600 mutation test Used on formalin-fixed, paraffin-embedded tissue, so biopsy specimens sent for routine histopathology are used Sensitive detection of the BRAF V600E mutation May also detect other mutations such as V600D, V600K, V600R
10 Additional methods for BRAF mutations testing Immunohistochemistry using anti-braf V600E antibody FIGURE 1. IHC staining with the VE1 antibody visualized using the chromogen diaminobenzene (brown staining) in metastatic melanoma. A, BRAF wild-type (wt) melanoma, which is negative for VE1. B, BRAF V600K-mutated melanoma, which is negative for VE1 (brown melanin pigment is present in a few melanoma cells). C, BRAF V600E-mutated melanoma strongly positive for VE1. D, Discordant case that was strongly VE1 positive and BRAF wt on original mutation testing. Upon retesting, a BRAF V600E mutation was detected. E, Lymph node containing scattered single and small clusters of strongly VE1-positive melanoma cells in a background of numerous lymphocytes. This case was BRAF wt on original and repeat mutation testing. F, Discordant fine-needle biopsy case showing negative VE1 staining in the cell block preparation. Mutation testing detected a BRAF V600E mutation. The cell block was prepared and fixed using techniques that differed from those used for all other cases (which utilized FFPE tissues). Long et al, Am J Surgical Pathology 2013
11 Additional formats for BRAF testing Targeted next generation sequencing panels Ability to assay for mutations in multiple oncogenes Used on formalin-fixed, paraffin-embedded tissue
12 Comparative Genomic Hybridization (CGH) CGH developed in the early 1990 s to expedite the identification and mapping of genome-wide DNA copy number alterations Deviations from normal copy numbers are now applied to cancer research by enabling the identification of genetic aberrations that occur in cancers the loss of tumor suppressor genes or amplification of oncogenes can be identified by comparing DNA from normal tissue to that from tumors March et al., JAAD 2015
13 Traditional CGH Arraybased CGH March et al., JAAD 2015
14 CGH in melanoma Determine if genetic criteria can distinguish melanoma from nevi. Examined 132 melanomas and 54 nevi 127 (96.2%) melanomas has genomic alterations 7 (13%) of nevi had gene rearrangements
15 CGH in melanoma The 7 nevi were Spitz nevi with gains on 11p Acral melanomas with alterations in 5p, 11q, 12q and 15 LMM loses at 17p and 13q
16 Busam, Seminars in Diagnostic Pathology 2013
17 CGH in Melanoma Multiple gains and losses (losses of 6q, 8p, 9p, and 10q, gains of 1q, 6p, 7, 8q, 17q, and 20q) In particular: Losses on 9p and 10, gains in 7 This is in contrast to nevi most lack genomic aberrations or have isolated changes Spitz nevi exhibit gains in chromosome 11p which is not seen in melanoma
18 Pitfalls Some melanomas are CGH negative Test sensitivity enough DNA for analysis, or admixture of melanoma cells with background nevus, stroma, etc True lack of copy number changes Benign lesions with copy number changes Differentiating homozygous from heterozygous deletions (better detected on FISH) Busam, Seminars in Diagnostic Pathology 2013
19 Fluorescence In Situ Hybridization (FISH) Method for determining the copy number of specific regions or sequences of DNA Short strands of fluorescently labeled DNA (probes) are used to label complementary target sequences in a given tissue sample Unlike CGH, FISH can detect balanced chromosomal translocations and single-point mutations BUT - the probes limit detection to prespecified DNA sequences (usually 4 probes) each probe must be tagged with a distinct fluorochrome that emits wavelengths of light that do not overlap with those emitted from the other fluorochromes CyTOF mass spectrometry of heavy metal tagged probes March et al., JAAD 2015
20 March et al., JAAD 2015
21 FISH for (unambiguous) melanocytic tumors Gerami et al., Am J Surg Path 2009 The algorithm correctly classified 72/83 melanomas 82/86 nevi Sensitivity 86.7% Specificity 95.4% 4/86 nevi were FISH positive (FP) 11/83 melanomas were FISH negative (FN) Probe set 5 yielded best results
22 What about for ambiguous melanocytic lesions? Histopath alone vs outcome: sensitivity 95%, specificity 52% FISH alone vs outcome: sensitivity 43%, specificity 80% Histopath AND FISH vs outcome: sensitivity 90% vs. specificity 76% Vergier et al., Modern Pathology 2011
23 Traditional probe set 6p25, 6q23, CEP6, 11q13 Sensitivity 75%, specificity 94% Enhanced probe set 6p25 (RREB1), 11q13 (CCND1), 9p21 (p16 and p15), 8q24 (Myc) Sensitivity 96%, specificity 98%
24 Advantages of FISH Permits detection of abnormal subpopulations within a heterogeneous tissue mixture Identification of much smaller populations of emerging clones of chromosomally aberrant cells is possible compared to CGH Visual correlation between a cell nucleus with an abnormal number of chromosomal loci and cytologic features is possible, which permits the verification of the identity of an affected cell Only small amounts of tissue are necessary for FISH
25 Limitations of FISH It only tests for aberrations in the targeted areas, which is usually limited to four chromosomal loci it doesn t analyze the entire set of chromosomes the way CGH does Focal view of the tumor False positives and false negatives occur, the latter varies based on the subtype of melanoma Tetraploidy may confuse the issue
26 Evaluating benign nevi and melanomas using a gene expression signature Candidate biomarker genes identified, based on differential expression in benign vs primary malignant melanocytic lesions reported in the literature or observed in practice Using a training set of 464 melanocytic lesions, a 23 gene signature yields an area under the curve of (AUC) 96% RT-PCR of RNA from FFPE tissue Clarke et al, Journal of Cutaneous Pathology 2015
27 Evaluating benign nevi and melanomas using a gene expression signature Clarke et al, Journal of Cutaneous Pathology 2015
28 Evaluating benign nevi and melanomas using a gene expression signature Clarke et al, Journal of Cutaneous Pathology 2015
29 Evaluating benign nevi and melanomas using a gene expression signature Histopathologically ambiguous lesions All 9 cases deemed to be malignant upon review by expert dermatopathologists were classified as malignant by the gene signature 4/8 cases deemed to be benign were classified as benign by gene signature Role for an indeterminate score? Metastatic lesions excluded from this study Not included in original cohorts. Clarke et al, Journal of Cutaneous Pathology 2015
30 Follow up study 1400 cases, divided into benign or malignant by 3 dermatopathologists. 91.5% sensitivity 92.5 specificity
31 Non-invasive test for melanoma
32 Assessing disease progression in stage 1 and 2 melanoma: Gene expression profile should predict biological behavior of melanoma Stage I and II melanomas represent a heterogeneous group with disease progression and death ranging from 3-55% within 5 years of diagnosis.
33 Assessing disease progression in stage 1 and 2 melanoma: Assessed published genomic analyses to develop prognostic genetic signature: Genes were selected based on differential expression Identified 28 prognostic genes and 3 control genes Assessed 260 primary melanomas used RT-PCR for these genes Analyzed levels of mrna using algorithm
34 Prognostic gene expression profiling (GEP) test 27 gene signature identified from microarray analysis: primary cutaneous melanoma vs. metastasis RT-PCR of RNA extracted from melanoma FFPE tissue Gerami et al, Clin Cancer Research 2015
35 Cellular functions represented in GEP signature Migration/chemotaxis/ metastasis CXCL14 SPP1 CLCA2 S100A9 S100A8 Differentiation/ proliferation CRABP2 SPRRIB BTG1 Chemokine/secreted molecules CCL14 MGP SPP1 Cell surface receptors TACST D2 CLCA2 ROBO1 Gap junction/cellular adhesion GJA1 DSC1 PPL Structural proteins MGP SPP1 CST6 Lymphocytic invasion LTA4H Angiogenesis regulator CXCL14 Transcription factor TRIM29 Extracellular functions KRT6B KRT14 Gerami, Clin Cancer Res 2013
36 Prognostic gene expression profiling (GEP) test Gene expression algorithm classifies tumors into: Class I: low metastatic risk Class 2: high metastatic risk Development set 5 year DFS Class 1-100%, validation-97% Class 2-38%, validation-31%
37 Prognostic gene expression profiling (GEP) test Median follow up time without evidence of LN involvement or distant metastasis = 7.6 years Gerami et al, Clin Cancer Research 2015
38 Acknowledgements: Emily Chu MD PhD Michael Ming MD PhD
6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationUpdate on Genetic Testing for Melanoma
Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationUpdate on Lymph Node Management in Melanoma
Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationMichael T. Tetzlaff MD, PhD
Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and
More informationMelanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors
Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department
More informationWhich melanoma patients benefit from genetic testing?
Which melanoma patients benefit from genetic testing? Michael A. Marchetti, MD Assistant Attending, Dermatology Service Memorial Sloan Kettering Cancer Center American Academy of Dermatology Annual Meeting
More information2/6/2018. Original Paradigm. Clonal Chromosomal A berrations. Only 20% of Spitz Nevi 95% 6p, 7q, 17q, 20q, 4q,8q, 1q, 11q. Isolated Gain in 11p
Molecular Diagnostics for Melanocytic Neoplasms: Moving towards a Revolution in the Management of Melanocytic Neoplasms Pedr am Gerami MD Associate Professor of Dermatology, Pathology and Pediatrics at
More informationLocally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.
Locally Advanced and Metastatic Melanoma Abel D. Jarell, MD, FAAD Adjunct Dartmouth School of Medicine, Hanover, NH Northeast Dermatology Associates, Portsmouth, NH Relevant disclosures What is the median
More informationPage 1 of 3. We suggest the following changes:
Page 1 of 3 Loren E. Clarke, M.D. Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 801.883.3470 Email: lclarke@myriad.com Date of Request: June 2017 NCCN Guidelines Panel:
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationMelanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018
Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018 Victor G. Prieto, MD, PhD Professor Depts. of Pathology and Dermatology University of Texas - MD Anderson Cancer Center
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationGene Expression Profiling in Malignancies: New Insights into Cancer Care
Gene Expression Profiling in Malignancies: New Insights into Cancer Care Surgical Grand Rounds February 8, 2017 Martin Fleming, M.D. Chief, Division of Surgical Oncology West Cancer Center University of
More informationTrue or False? Nearly twice as many SLNB negative compared to SLNB positive patients will ultimately die of metastatic melanoma.
qrt-pcr Based Methods for Prognosis of Melanoma Pedr am Gerami MD Pr ofessor of Dermatology, Pathology and Pediatrics Nor thwestern University Dir ector Melanoma Program, Northwestern Skin Cancer Institute
More informationPatricia Chevez-Barrrios AAOOP-USCAP /12/2016
Biomarkers in Ocular Melanoma Patricia Chévez-Barrios, MD Pathology and Genomic Medicine, Houston Methodist Hospital Professor of Pathology and Laboratory Medicine and Ophthalmology, Weill Cornell Medical
More informationMolecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco
Molecular Aspects of Melanocytic Neoplasia Iwei Yeh MD, PhD University of California, San Francisco Thanks to: Boris Bastian Timothy McCalmont Philip LeBoit Beth Ruben Jeff North Laura Pincus Thaddeus
More informationCase 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:
Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is: A. Desmoplastic Spitz naevus B. Atypical Spitz Tumour C. Spitzoid melanoma D. Deep penetrating naevus E. Spitz naevus Case 26: M
More informationUpdate on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy
Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology,
More informationThere is NO single Melanoma Stain. > 6000 Mutations in Melanoma. What else can be done to discriminate atypical nevi from melanoma?
Las Vegas Fall Clinical 2016: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationSupplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the
Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the deep dermis. (b) The melanocytes demonstrate abundant
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this study the authors analysed 18 deep penetrating nevi for oncogenic genomic changes (single nucleotide variations, insertions/deletions,
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationPODIATRIC PATHOLOGY REPORT IS;RL;MMR; 1 of 1. A Copy was sent to: DR. JANE DOE 456 SAMPLE BLVD NEW YORK, NY DIAGNOSIS
Batch#: 10388 Tel#: 1-888-CUPTH ccession: Obtained: Received: 12:02 pm PTIENT: JCK JONES 12548 MIN ST FLUSHING, NY 11365 (718) 555-2541 DOB: 01/02/19XX Specimen Final Report Date cct#: 1018 ge: 57 Sex:
More informationGene Expression Profiling for Cutaneous Melanoma
Gene Expression Profiling for Cutaneous Melanoma Policy Number: 2.04.146 Last Review: 8/1/2018 Origination: 08/2018 Next Review: 8/1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationStructural Variation and Medical Genomics
Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling for Cutaneous Melanoma Page 1 of 28 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling for Cutaneous Melanoma Professional
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationRapid BRAF mutation detection in melanoma patients by immunohistochemistry
http://dx.doi.org/10.17202/juso.2017.4.1 Journal of Universal Science Vol 4(1): 1-5, 2017 Rapid BRAF mutation detection in melanoma patients by immunohistochemistry László FÜLÖP 1, Katalin GÖTZER 1, Erzsébet
More informationGene Expression Profiling for Cutaneous Melanoma
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More information10/2/17. MELTUMP, SAMPUS, AST.An Algorithmic Approach to Challenging (Often Borderline) Melanocytic Tumors. An Introduction to SNP Arrays
MELTUMP, SAMPUS, AST.An Algorithmic Approach to Challenging (Often ) Melanocytic Tumors An Introduction to SNP Arrays Rajiv M. Patel, M.D. RCPA NZ ASM 2017 (11:45-12:30pm, Saturday, 23-09-17) Why do we
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationIntegrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma
Integrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma Association for Molecular Pathology United States and Canadian Academy of Pathology Companion
More informationDermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia
Dermatopathology Dr. Rafael Botella Estrada. Hospital La Fe de Valencia Melanoma and mimics Dr. Martin Mihm Malignant lesions result from the accumulation of mutations Class I lesions (benign) Class II
More informationChallenges in Melanoma Diagnosis and Management
Challenges in Melanoma Diagnosis and Management Winter Clinical Dermatology Conference - Hawaii Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center DISCLOSURE OF
More informationAmoyDx TM BRAF V600E Mutation Detection Kit
AmoyDx TM BRAF V600E Mutation Detection Kit Detection of V600E mutation in the BRAF oncogene Instructions For Use Instructions Version: B3.1 Date of Revision: April 2012 Store at -20±2 o C 1/5 Background
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationThe Enigmatic Spitz Lesion
The Enigmatic Spitz Lesion The Dawn of Spitz S Spitz Sophie Spitz Melanomas of Childhood ; Am J Pathol 1948 1910-1956 13 children (18 mo - 12 yrs) 12/13 had a benign clinical course Sophie Spitz Born 1910
More informationApproximately 2% of the United States population
Differentiation of Malignant Melanoma From Benign Nevus Using a Novel Genomic Microarray With Low Specimen Requirements Wells M. Chandler, MD; Leslie R. Rowe, MS; Scott R. Florell, MD; Mona S. Jahromi,
More informationRevisiting Determinants of Prognosis in Cutaneous Melanoma
Review Article Revisiting Determinants of Prognosis in Cutaneous Melanoma Sarah A. Weiss MD 1,2 ; Douglas Hanniford PhD 2,3 ; Eva Hernando PhD 2,3 ; and Iman Osman MD 1,2,4 The American Joint Committee
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationGene Expression Profiling for Melanoma
Medical Policy Manual Genetic Testing, Policy No. 29 Gene Expression Profiling for Melanoma Next Review: April 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationDiagnosis of melanocytic proliferations remains one of
Update on Fluorescence In Situ Hybridization in Melanoma State of the Art Pedram Gerami, MD; Artur Zembowicz, MD, PhD N Context. Recent advances in understanding the molecular basis of melanoma have resulted
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Fig. 1: Quality assessment of formalin-fixed paraffin-embedded (FFPE)-derived DNA and nuclei. (a) Multiplex PCR analysis of unrepaired and repaired bulk FFPE gdna from
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More information21/07/2017. The «gray zone» of diagnosis is visible. Nevus Atypical nevus Melanoma. Melanoma ex-blue nevus
Update on the Clinico- Pathological and Molecular Diagnosis of Melanocytic Lesions None to declare Conflicts of interest Belfast pathology Arnaud de la Fouchardière MD, PhD Lyon, France What is new? Today
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationRECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER
Technology Transfer in Diagnostic Pathology. 6th Central European Regional Meeting. Cytopathology. Balatonfüred, Hungary, April 7-9, 2011. RECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER Philippe
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationThesis submitted for the degree of. Doctor of Medicine. at the University of Leicester. Dr David Allan Moore BMedSci MBBS (London)
DUPLEX RATIO TESTS AS DIAGNOSTIC TISSUE BIOMARKERS IN MALIGNANT MELANOMA Thesis submitted for the degree of Doctor of Medicine at the University of Leicester by Dr David Allan Moore BMedSci MBBS (London)
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationTracking skin cancers and melanoma at the microscopic level
Tracking skin cancers and melanoma at the microscopic level Rosalie Elenitsas, M.D. Professor of Dermatology Director of Dermatopathology Hospital of the University of Pennsylvania May 12, 2017 Outline
More informationSUPPLEMENTARY APPENDIX
SUPPLEMENTARY APPENDIX 1) Supplemental Figure 1. Histopathologic Characteristics of the Tumors in the Discovery Cohort 2) Supplemental Figure 2. Incorporation of Normal Epidermal Melanocytic Signature
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationDetermination of gene signatures to subgroup melanoma patients using novel branched DNA hybridization assays
APPLICATION NOTE QuantiGene Plex and ViewRNA ISH Assays Determination of gene signatures to subgroup melanoma patients using novel branched DNA hybridization assays Poster presentation from the 4th International
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationA diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
Modern Pathology (2016), 1 15 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 1 A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
More informationDako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)
INTERPRETATION Dako Agilent Pathology Solutions IQFISH Interpretation Guide ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) IT S ABOUT TIME For In Vitro Diagnostic Use ALK, ROS1,
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More information